Results of recent clinical trials for pediatric AML
| Study . | Years of enrollment . | Eligible age, y . | No. of patients . | CR rate,* % . | Outcome . | Key points . |
|---|---|---|---|---|---|---|
| St Jude AML029 | 2002-2008 | ≤ 21 | 216 | 94 | 3-y EFS: 63% | Risk-adapted therapy was based on molecular genetics and MRD |
| 3-y OS: 71% | High-dose cytarabine during induction was not beneficial | |||||
| AML-BFM 9811,26 | 1998-2003 | < 18 | 473 | 88 | 5-y EFS: 49% | G-CSF did not decrease the incidence of infection or infection-related mortality |
| 5-y OS: 62% | Shorter, intensive consolidation cycles did not improve outcome | |||||
| MRC AML1212 | 1995-2002 | < 16 | 529 | 92 | 10-y EFS: 54% | No differences in EFS or OS rates between mitoxantrone- and daunorubicin-based inductions |
| 10-y OS: 64% | No difference in EFS or OS rates between 4 and 5 courses of therapy | |||||
| NOPHO-AML 200413 | 2004-2009 | ≤ 18 | 151 | 92 | 3-y EFS: 57% | Intensity of therapy based on early response to therapy |
| 3-y OS: 69% | ||||||
| AML9910 | 2000-2002 | ≤ 18 | 240 | 95 | 5-y EFS: 62% | Intensive use of high-dose cytarabine |
| 5-y OS: 76% | Six courses of therapy | |||||
| COG AAML03P179 | 2003-2005 | ≤ 21 | 350 | 87 | 3-y EFS: 53% | Safe to add gemtuzumab ozogamicin to first and fourth courses of therapy |
| 3-y OS: 66% |
| Study . | Years of enrollment . | Eligible age, y . | No. of patients . | CR rate,* % . | Outcome . | Key points . |
|---|---|---|---|---|---|---|
| St Jude AML029 | 2002-2008 | ≤ 21 | 216 | 94 | 3-y EFS: 63% | Risk-adapted therapy was based on molecular genetics and MRD |
| 3-y OS: 71% | High-dose cytarabine during induction was not beneficial | |||||
| AML-BFM 9811,26 | 1998-2003 | < 18 | 473 | 88 | 5-y EFS: 49% | G-CSF did not decrease the incidence of infection or infection-related mortality |
| 5-y OS: 62% | Shorter, intensive consolidation cycles did not improve outcome | |||||
| MRC AML1212 | 1995-2002 | < 16 | 529 | 92 | 10-y EFS: 54% | No differences in EFS or OS rates between mitoxantrone- and daunorubicin-based inductions |
| 10-y OS: 64% | No difference in EFS or OS rates between 4 and 5 courses of therapy | |||||
| NOPHO-AML 200413 | 2004-2009 | ≤ 18 | 151 | 92 | 3-y EFS: 57% | Intensity of therapy based on early response to therapy |
| 3-y OS: 69% | ||||||
| AML9910 | 2000-2002 | ≤ 18 | 240 | 95 | 5-y EFS: 62% | Intensive use of high-dose cytarabine |
| 5-y OS: 76% | Six courses of therapy | |||||
| COG AAML03P179 | 2003-2005 | ≤ 21 | 350 | 87 | 3-y EFS: 53% | Safe to add gemtuzumab ozogamicin to first and fourth courses of therapy |
| 3-y OS: 66% |
CR indicates complete remission.
CR rate after 2 courses of induction therapy.